Auranofin exerts antibacterial activity against *Neisseria gonorrhoeae* in a female mouse model of genital tract infection

Ahmed E. M. Elhassanny¹, Nader S. Abutaleb¹, Mohamed N. Seleem¹,²*

¹ Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America, ² Center for Emerging, Zoonotic and Arthropod-borne Pathogens, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America

* seleem@vt.edu

Abstract

*Neisseria gonorrhoeae* has been classified by the U.S. Centers for Disease Control and Prevention as an urgent threat due to the rapid development of antibiotic resistance to currently available antibiotics. Therefore, there is an urgent need to find new antibiotics to treat gonococcal infections. In our previous study, the gold-containing drug auranofin demonstrated potent *in vitro* activity against clinical isolates of *N. gonorrhoeae*, including multidrug-resistant strains. Therefore, the aim of this study was to investigate the *in vivo* activity of auranofin against *N. gonorrhoeae* using a murine model of vaginal infection. A significant reduction in *N. gonorrhoeae* recovered from the vagina was observed for infected mice treated with auranofin compared to the vehicle over the course of treatment. Relative to the vehicle, after three and five days of treatment with auranofin, a 1.04 (91%) and 1.40 (96%) average log₁₀ reduction of recovered *N. gonorrhoeae* was observed. In conclusion, auranofin has the potential to be further investigated as a novel, safe anti-gonococcal agent to help meet the urgent need for new antimicrobial agents for *N. gonorrhoeae* infection.

Introduction

*Neisseria gonorrhoeae* is the causative agent of gonorrhea, which is the second-most reported sexually transmitted disease in the United States. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 616,000 cases of gonorrhea were reported in the U.S in 2019, which represents a 56% increase since 2015 [1]. Furthermore, the World Health Organization (WHO) estimated 87 million new gonorrhea infections occurred worldwide in 2016 [2]. However, the number of reported cases does not represent the true burden of gonorrhea because many infections are asymptomatic.

*N. gonorrhoeae* mainly infects the cervix in females and the anterior urethra in males. Symptoms of gonorrhea mainly include purulent discharge and inflammation of the cervix or urethra. Untreated cervical infection may lead to serious complications, such as pelvic inflammatory disease, ectopic pregnancy, and infertility [3, 4]. Pregnant women infected with *N.
gonorrhoeae have a high risk of vertical transmission to the fetus/newborn, which may lead to septic abortion and neonatal conjunctivitis [5]. In males, untreated urethritis due to gonorrhea may cause epididymitis or prostatitis. In rare cases, untreated urogenital gonorrhea can disseminate outside the genitals and cause septic arthritis, endocarditis, and meningitis in both males and females [3, 4]. Moreover, N. gonorrhoeae infection can predispose people to the acquisition and transmission of human immunodeficiency virus infection [6].

Since 1940, gonorrhea has been treated with a range of antibiotics, including sulfonamides, penicillin, tetracycline, and ciprofloxacin. However, the development of resistance by strains of N. gonorrhoeae to these drugs led to discontinuation of their use [7]. In 2018, treatment recommendations for gonorrhea included ceftriaxone in combination with azithromycin [8]. However, 5.1% of N. gonorrhoeae isolates had elevated azithromycin minimum inhibitory concentration (MIC) values in 2019 [1]. As a result, in December 2020, the CDC removed azithromycin from the treatment guidelines for gonorrhea. Currently, the CDC recommends a single 500 mg intramuscular dose of ceftriaxone for uncomplicated gonorrhea [9]. Further compounding the problem, N. gonorrhoeae isolates with reduced susceptibility to ceftriaxone have been reported in the U.S. and worldwide [10–13]. Due to its rapid and progressive development of resistance to currently available antibiotics, N. gonorrhoeae is classified by the CDC as an urgent threat [14]. Therefore, there is an urgent need for new antibiotics to treat gonococcal infections. Currently, there are only two new antimicrobial agents, zoliflodacin and gepotidacin, that have shown very promising results in Phase 2 clinical trials to treat gonorrhea [15–17]; however, more anti-gonococcal agents are urgently needed.

Auranofin is a gold-containing compound that was approved by the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis. Auranofin has demonstrated excellent antibacterial activity against drug-resistant Gram-positive bacteria, including multidrug-resistant Staphylococcus aureus, Clostridoides difficile, vancomycin-resistant Enterococcus faecalis and E. faecium, Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus agalactiae [18–25]. Moreover, auranofin possesses antibacterial activity against Mycobacterium tuberculosis [26]. Auranofin also demonstrated antimicrobial activity against Gram-positive bacteria in different mouse models, including skin infection, systemic, and peritonitis models [18, 20, 21, 25–27]. Auranofin is considered safe for systemic administration, with no serious side effects or long-term safety concerns [28]. It is now being investigated for the treatment of amebiasis or giardiasis in a Phase II clinical trial (NCT02736968).

Auranofin was previously identified as a promising anti-gonococcal agent in a wide-scale drug repurposing screen using the Prestwick Chemical Library [29]. In addition, in our previous study, we investigated the activity of auranofin against N. gonorrhoeae in vitro [30]. Auranofin exhibited potent antibacterial activity against clinical isolates of N. gonorrhoeae, including multidrug-resistant strains, as manifested by MIC values that were as low as 0.03 μg/mL. Additionally, a time-kill assay demonstrated that auranofin exhibited rapid bactericidal activity in vitro against N. gonorrhoeae. Moreover, auranofin eradicated intracellular N. gonorrhoeae in infected endocervical cells (END1/E6E7), outperforming ceftriaxone, the first-line drug [30]. Building upon these promising in vitro results, in this study we investigated the in vivo activity of auranofin against N. gonorrhoeae using a mouse model of vaginal infection.

Materials and methods

Bacterial strains, chemicals, and media

The FA1090 (ATCC 700825) strain of N. gonorrhoeae was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). GC agar base, Chocolate II agar, dried bovine hemoglobin, brucella broth and IsoVitaleX were obtained from Becton, Dickinson, and
Company (Cockeysville, MD). Heart infusion agar was obtained from Hardy Diagnostics (Santa Maria, CA). Yeast extract and dextrose were obtained from Fisher Bioreagents (Fair Lawn, NJ). Auranofin, hematin, pyridoxal, and nicotinamide adenine dinucleotide (NAD) were obtained from Chem-Impex International (Wood Dale, IL). Protease peptone and VCNT supplement were purchased from Oxoid (Lenexa, KS). Phosphate-buffered saline (PBS) was obtained from Corning (Manassas, VA). Ceftriaxone, azithromycin and saponin were obtained from TCI America (Portland, OR) Tween 80 was obtained from Acros Organics (Fair Lawn, NJ). Estradiol pellets (5-mg, 21-day controlled-release) were purchased from Innovative Research of America (Sarasota, FL). Dacron swabs were purchased from the Medical Packaging Corporation (Camarillo, CA).

**Minimum inhibitory concentration**

The MIC values of auranofin, azithromycin, and ceftriaxone against *N. gonorrhoeae* FA1090 were determined, as described previously [31–34]. Briefly, a bacterial suspension equivalent to a McFarland standard of 1.0 was prepared and diluted in Brucella Broth supplemented with yeast extract, dextrose, proteose-peptone, NAD, pyridoxal, and hematin to obtain a bacterial count of $1 \times 10^6$ CFU/mL. Diluted bacteria were incubated with serial dilutions of auranofin, azithromycin, or ceftriaxone at 37˚C for 24 hours in the presence of 5% CO$_2$.

**Evaluating the activity of auranofin against *N. gonorrhoeae* in mice**

**Preparation of *N. gonorrhoeae* for the animal study.** *N. gonorrhoeae* FA1090 was streaked on GC agar plates and incubated at 37˚C for 20 hours in the presence of 5% CO$_2$. Separate colonies were used to prepare a bacterial suspension in sterile PBS. The bacterial suspension was filtered to remove bacterial aggregates and then diluted with PBS to reach a concentration of $\sim 10^8$ CFU/mL. The bacterial count was confirmed by dilution and plating onto GC agar plates.

**Mouse model of *N. gonorrhoeae* vaginal infection.** Animal experiments were reviewed, approved, and performed under the guidelines of Virginia Polytechnic Institute and State University Institutional Animal Care and Use Committee (IACUC). Animal experiments were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal studies are in compliance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. According to the approved animal protocol, if any animal meets more than two of the group I criteria for 48 hours with no improvement, it will be closely monitored and a veterinarian will be consulted to determine how to proceed (euthanize, treat or continue to monitor). If any animal exhibits any one of the group II criteria, it will be euthanized promptly. Group I Criteria: a. rough coat and unkempt b. Eyes full or partially closed for 10 min c. Markedly diminished resistance to being handled (grimace response) d. Markedly decreased movement/lethargy e. hunched posture f. distended abdomen. Group II Criteria: a. Inability to eat or drink b. moribund/unresponsive c. Failure to right self when placed on back d. Dyspnea e. 15% or more loss in the body weight. A total of 30 animals were used in the study and all of them were euthanized at the end of experiment using carbon dioxide. No humane end point was reached. The duration of the study was 10 days. Animal health and behavior were monitored twice daily. Animal welfare considerations were taken, including efforts to minimize suffering and distress. Isoflurane was given by inhalation to anaesthetize mice during the steps that are associated with pain (vaginal swab or using the trochar). Research staff had all the necessary training including animal injection, euthanasia, oral gavage and the use of trochar.
Auranofin antibacterial activity against Neisseria gonorrhoeae in a female mouse model

*N. gonorrhoeae* infection was established in the vagina of mice, as described previously by Raterman and Jerse [35]. Fig 1 presents a schematic of the mice study. Briefly, female 8-week-old ovariectomized BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were anesthetized using isoflurane inhalation and shaved. Mice were subsequently implanted with 5-mg, 21-day controlled-release estradiol pellets subcutaneously using precision trocars (Innovative Research of America, Sarasota, FL), and the incision was glued using 3M Vetbond Tissue Adhesive (3M, Saint Paul, MN). Two days after pellet implantation, mice were inoculated intravaginally with $2.3 \times 10^6$ CFU of *N. gonorrhoeae* FA1090. Mice were injected intraperitoneally with 4 mg/L of vancomycin and 24.0 mg/L of streptomycin on Days −2 through +1. Drinking water was replaced on Day −2 with water containing 0.4 mg/L trimethoprim. Trimethoprim-containing water was refreshed every other day for the duration of the experiment. Streptomycin sulfate (2.4 mg/L) was added to the water after Day +1. Two days post-infection, mice were randomly allocated into groups (n = 10) and administered either auranofin (0.25 mg/kg) or vehicle (10% DMSO, 10% Tween 80, 80% PBS) via the oral route for five consecutive days. As a positive control, one group of mice received a single intraperitoneal dose of ceftriaxone (15 mg/kg). *N. gonorrhoeae* vaginal colonization was quantified by collecting vaginal swabs daily. Moisten Dacron swabs were gently inserted into the vagina of anesthetized mice and then suspended into 0.1 mL of GC broth containing 0.05% saponin. Samples were serially diluted and plated on GC agar supplemented with VCNT (contains 600 μg of vancomycin, 1.5 mg of colistin, 2500 units of nystatin, and 1 mg of trimethoprim lactate per liter). To monitor the presence of commensal flora that could potentially inhibit the growth of *N. gonorrhoeae*, vaginal swabs were streaked on heart infusion agar and the resulting growth was Gram stained. Contaminated samples were excluded from the experiment.

### Statistical analyses

Data were analyzed via two-way ANOVA with post-hoc Dunnett’s test for multiple comparisons, utilizing GraphPad Prism version 8 for Windows (GraphPad Software, La Jolla, CA).

### Results and discussion

The *in vitro* antibacterial activity of auranofin against *N. gonorrhoeae* FA1090 (ATCC 700825) was determined. Consistent with our previous study, auranofin displayed potent anti-gonococcal activity and inhibited the growth of *N. gonorrhoeae* FA1090 at a concentration of 0.125 μg/mL. Azithromycin and ceftriaxone were used as positive controls. They inhibited the growth of the tested *N. gonorrhoeae* strain at a concentration of 0.06 μg/mL (azithromycin) and 0.002 μg/mL (ceftriaxone), respectively.

The *in vivo* activity of auranofin against *N. gonorrhoeae* FA1090 was evaluated using a female mouse model of *N. gonorrhoeae* genital tract infection, as previously described [35]. This model has been successfully used to study host-pathogen interactions and the genetic basis for antibiotic resistance [36–39]. Importantly, this model permits the testing of antimicrobial agents, immunotherapies, and vaccines against *N. gonorrhoeae* infection [40–45]. It has been established that *N. gonorrhoeae* can colonize the female genital tract of mice when inoculated into the vagina during the diestrus or anestrus stages of the estrous cycle [46]. The duration of infection with *N. gonorrhoeae* can be prolonged via treatment of mice with 17β-estradiol [47].

In this study, we established an *N. gonorrhoeae* infection in female ovariectomized BALB/c mice that were subcutaneously implanted with a 5-mg, 21-day controlled-release estradiol pellet two days before the infection (Fig 1). Ovariectomized mice were used because they do not need to be staged prior to estradiol treatment. On the other hand, intact (regular) mice require
staging (two times, three days apart) to identify the mice in the proper stage (diestrus or anestrus). Thus, if using regular mice, the total number of animals should be increased, as some mice may not be in the correct stage to establish \( N. \) gonorrhoeae infection. Additionally, the recovery of \( N. \) gonorrhoeae from ovariectomized mice is better than that from intact mice, because there are no observed fluctuations in the number of recovered \( N. \) gonorrhoeae from ovariectomized mice \([35, 36]\). Thus, the use of ovariectomized mice in our study eliminated the unnecessary use of extra mice and improved the recovery of \( N. \) gonorrhoeae. In this study, mice were administered an antibiotic cocktail throughout the experiment to avoid the overgrowth of vaginal commensal flora that could inhibit \( N. \) gonorrhoeae infection (Fig 1). The overgrowth of vaginal microbiota can be due to estrogen-induced proliferation of vaginal cells that result in elevated levels of free glycogen \([35]\). The establishment of \( N. \) gonorrhoeae infection and the effect of different treatments on \( N. \) gonorrhoeae colonization of the vagina of mice were tested by collecting vaginal swabs daily and plating on GC agar supplemented with vancomycin, colistin, nystatin, and trimethoprim (VCNT).

Previous studies have shown that auranofin has a good safety profile \([28]\). Chronic exposure of patients to auranofin over extended periods of time was safe with no cumulative toxicity observed over five years \([28]\). The usual adult dosage of auranofin is 6–9 mg daily for up to six months, which is a much longer course of treatment than what would be expected for
auranofin as an antibacterial agent \[20, 49\]. Consequently, the dose used in this study, (0.25 mg/kg), is within range of clinically-administered human doses. In the present study, auranofin-treated mice, as expected, showed no weight loss or other obvious comorbidities. Therefore, auranofin is a promising, safe drug to be administered alone or in combination with other antibiotics to treat gonorrheal infections.

In our previous study, auranofin showed excellent activity against \textit{N. gonorrhoeae} strains in vitro as demonstrated by MIC values and a time-kill assay \[30\]. Additionally, auranofin outperformed ceftriaxone in eliminating intracellular \textit{N. gonorrhoeae} infection of endocervical cells (END1/E6E7) \[30\]. In this study, mice treated with auranofin at a dose of 0.25 mg/kg showed an average reduction in gonococcal burden by 1.4-log\(_{10}\) (96%) relative to the vehicle after five days of treatment. It is tempting to hypothesize that increasing the dose of auranofin or the duration of treatment may result in a much better anti-gonococcal effect in mice. Additionally, since gonococcal infections have previously been treated with a combination of two drugs, azithromycin and ceftriaxone, we propose that the combination of auranofin with azithromycin or ceftriaxone may possess a synergistic effect against \textit{N. gonorrhoeae} in vivo. However, this must be investigated in a future study.

**Supporting information**

S1 Data. Minimal underlying data set.

(XLSX)

**Author Contributions**

Conceptualization: Ahmed E. M. Elhassanny, Mohamed N. Seleem.
**Data curation:** Nader S. Abutaleb.

**Formal analysis:** Ahmed E. M. Elhassanny, Nader S. Abutaleb.

**Funding acquisition:** Mohamed N. Seleem.

**Investigation:** Ahmed E. M. Elhassanny, Nader S. Abutaleb.

**Methodology:** Ahmed E. M. Elhassanny, Nader S. Abutaleb.

**Supervision:** Mohamed N. Seleem.

**Writing – original draft:** Ahmed E. M. Elhassanny.

**Writing – review & editing:** Ahmed E. M. Elhassanny, Mohamed N. Seleem.

**References**

1. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2019. Atlanta: U.S. Department of Health and Human Services.
2. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, et al. Chlamydia, gonorrhea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019; 97(8):548–62P. https://doi.org/10.2471/BLT.18.228486 PMID: 31384073
3. Lovett A, Duncan JA. Human Immune Responses and the Natural History of Neisseria gonorrhoeae Infection. Front Immunol. 2018; 9:3187. https://doi.org/10.3389/fimmu.2018.03187 PMID: 30838004
4. Stevens JS, Criss AK. Pathogenesis of Neisseria gonorrhoeae in the female reproductive tract: neutrophilic host response, sustained infection, and clinical sequelae. Curr Opin Hematol. 2018; 25(1):13–21. https://doi.org/10.1097/MOH.0000000000000394 PMID: 29016383
5. Woods CR. Gonococcal infections in neonates and young children. Semin Pediatr Infect Dis. 2005; 16(4):258–70. https://doi.org/10.1053/spid.2005.06.006 PMID: 16210106
6. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999; 75(1):3–17. https://doi.org/10.1136/sti.75.1.3 PMID: 10483357
7. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014; 27(3):587–613. https://doi.org/10.1128/CMR.00100-14 PMID: 24982323
8. Jefferson A, Smith A, Fasinu PS, Thompson DK. Sexually Transmitted Neisseria gonorrhoeae Infections-Update on Drug Treatment and Vaccine Development. Medicines (Basel). 2021; 8(2). https://doi.org/10.3390/medicines8020011 PMID: 3562607
9. St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, et al. Update to CDC’s Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(50):1911–6. https://doi.org/10.15585/mmwr.mm6950a6 PMID: 33332296
10. Picker MA, Knoblock RJ, Hansen H, Bautista I, Griego R, Barber L, et al. Notes from the Field: First Case in the United States of Neisseria gonorrhoeae Harborinf Emerging Mosaic penA60 Allele, Conferring Reduced Susceptibility to Cefixime and Ceftriaxone. MMWR Morb Mortal Wkly Rep. 2020; 69(49):1876–7. https://doi.org/10.15585/mmwr.mm6949a5 PMID: 33301430
11. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sedaoua P. High-level ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012; 56(3):1273–80. https://doi.org/10.1128/AAC.00570-11 PMID: 22155830
12. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011; 55(7):3538–45. https://doi.org/10.1128/AAC.00325-11 PMID: 21576437
13. Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012; 67(8):1658–60. https://doi.org/10.1093/jac/dks162 PMID: 22566592
14. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services:1[–113 pp.].
15. Unemo M, Ahlstrand J, Sanchez-Buso L, Day M, Aanensen D, Golparian D, et al. High susceptibility to zolfilodacin and conserved target (GyrB) for zolfilodacin among 1209 consecutive clinical Neisseria
Auranofin antibacterial activity against Neisseria gonorrhoeae in a female mouse model

gonorrhoeae isolates from 25 European countries, 2018. J Antimicrob Chemother. 2021; 76(5):1221–8. https://doi.org/10.1093/jac/dkab024 PMID: 33564854

16. Bradford PA, Miller AA, O’Donnell J, Mueller JP. Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrhoeae, Including Multi-Drug-Resistant Isolates. ACS Infect Dis. 2020; 6(6):1332–45. https://doi.org/10.1021/acsinfecdis.0c00021 PMID: 32329999

17. Scangarella-Oman NE, Hossain M, Dixon PB, Ingraham K, Min S, Tiffany CA, et al. Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gatifloxacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae. Antimicrobial Agents Chemother. 2018;62(12). https://doi.org/10.1128/AAC.01221-18 PMID: 32049694

18. Mohammad H, Abutaleb NS, Seleem MN. Auranofin Rapidly Eradicates Methicillin-resistant Staphylococcus aureus (MRSA) in an Infected Pressure Ulcer Mouse Model. Sci Rep. 2020; 10(1):7251. https://doi.org/10.1038/s41598-020-64352-2 PMID: 32350417

19. Abutaleb NS, Seleem MN. In vivo efficacy of auranofin in a hamster model of Clostridiodioides difficile infection. Sci Rep. 2021; 11(1):7093. https://doi.org/10.1038/s41598-021-86595-3 PMID: 33782498

20. Abutaleb NS, Seleem MN. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridiodioides difficile infection. Sci Rep. 2020; 10(1):7701. https://doi.org/10.1038/s41598-020-64882-9 PMID: 32382070

21. Abutaleb NS, Seleem MN. Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies. Int J Antimicrob Agents. 2020; 55(3):10582. https://doi.org/10.1016/j.ijantimicag.2019.10.009 PMID: 31669742

22. AbdelKhalek A, Abutaleb NS, Mohammad H, Seleem MN. Antibacterial and antivirulence activities of auranofin against Clostridium difficile. Int J Antimicrob Agents. 2019; 53(1):54–62. https://doi.org/10.1016/j.ijantimicag.2018.09.018 PMID: 30273668

23. AbdelKhalek A, Abutaleb NS, Elmagarmid KA, Seleem MN. Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci. Sci Rep. 2018; 8(1):8353. https://doi.org/10.1038/s41598-018-26674-0 PMID: 29844350

24. Thangamani S, Mohammad H, Abushahaba MF, Sobreira TJ, Hedrick VE, Paul LN, et al. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens. Sci Rep. 2016; 6:22571. https://doi.org/10.1038/srep22571 PMID: 26936660

25. Aquinagalde L, Diez-Martinez R, Yusle J, Royo I, Gil C, Lasa I, et al. Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections. J Antimicrob Chemother. 2015; 70(9):2608–17. https://doi.org/10.1093/jac/dkv163 PMID: 26142477

26. Harbut MB, Vilcheze C, Luo X, Hensler ME, Guo H, Yang B, et al. Auranofin exerts broad-spectrum bacterial activities by targeting thiol-redox homeostasis. Proc Natl Acad Sci U S A. 2015; 112(14):4453–8. https://doi.org/10.1073/pnas.1504022112 PMID: 25831516

27. Thangamani S, Mohammad H, Abushahaba MF, Sobreira TJ, Seleem MN. Repurposing auranofin for the treatment of cutaneous staphylococcal infections. Int J Antimicrob Agents. 2016; 47(3):195–201. https://doi.org/10.1016/j.ijantimicag.2015.12.016 PMID: 26895605

28. Blodgett RC Jr., Pietrusko RG. Long-term efficacy and safety of auranofin: a review of clinical experience. Scand J Rheumatol Suppl. 1986; 63:67–78. PMID: 3110943

29. Foerster S, Gustafsson TN, Brochado AR, Desilvestro V, Typas A, Unemo M. The first wide-scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive molecules) against Neisseria gonorrhoeae identifies high in vitro activity of auranofin and many additional drugs. APMIS. 2020; 128(3):242–50. https://doi.org/10.1111/apm.13014 PMID: 31811739

30. Elkashif A, Seleem MN. Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae. Sci Rep. 2020; 10(1):5602. https://doi.org/10.1038/s41598-019-02668-3 PMID: 32221472

31. Alhashimi M, Mayhoub A, Seleem MN. Repurposing salicylamide for combating multidrug-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2019. https://doi.org/10.1128/AAC.01225-19 PMID: 31570391

32. Naclerio GA, Abutaleb NS, Alhashimi M, Seleem MN, Sintim HO. N-[(3,4-Oxadiazol-2-y]l)Benzamides as Antibacterial Agents against Neisseria gonorrhoeae. Int J Mol Sci. 2021; 22(5). https://doi.org/10.3390/ijms22052427 PMID: 33671065

33. Hewitt CS, Abutaleb NS, Elhassanny AEM, Nocentini A, Cao X, Amos DP, et al. Structure-Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae. ACS Infect Dis. 2021. https://doi.org/10.1021/acsinfecdis.1c00055 PMID: 33765392

34. Seong YJ, Alhashimi M, Mayhoub A, Mohammad H, Seleem MN. Repurposing Fenamic Acid Drugs To Combat Multidrug-Resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2020; 64(7). https://doi.org/10.1128/AAC.02206-19 PMID: 32393483
35. Raterman EL, Jerse AE. Female Mouse Model of Neisseria gonorrhoeae Infection. Methods Mol Biol. 2019; 1997:41–29. https://doi.org/10.1007/978-1-4939-9496-0_24 PMID: 31119637

36. Jerse AE, Wu H, Packiam M, Vonck RA, Begum AA, Garvin LE. Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections. Front Microbiol. 2011; 2:107. https://doi.org/10.3389/fmicb.2011.00107 PMID: 21747807

37. Kunz AN, Begum AA, Wu H, D’Ambrozo JA, Robinson JM, Shafer WM, et al. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J Infect Dis. 2012; 205(12):1821–9. https://doi.org/10.1093/infdis/jis277 PMID: 22492860

38. Warner DM, Shafer WM, Jerse AE. Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol. 2008; 70(2):462–78. https://doi.org/10.1111/j.1365-2958.2008.06424.x PMID: 18761689

39. Liu Y, Liu W, Russell MW. Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells. Mucosal Immunol. 2014; 7(1):165–76. https://doi.org/10.1038/mi.2013.36 PMID: 23757303

40. Butler MM, Waidyaratne SL, Connolly KL, Jerse AE, Chai W, Lee RE, et al. Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections. Antimicrob Agents Chemother. 2018; 62(5). https://doi.org/10.1128/AAC.00325-18 PMID: 29483122

41. Schmitt DM, Connolly KL, Jerse AE, Detrick MS, Horzempa J. Antibacterial activity of resazurin-based compounds against Neisseria gonorrhoeae in vitro and in vivo. Int J Antimicrob Agents. 2016; 48 (4):367–72. https://doi.org/10.1016/j.ijantimicag.2016.06.009 PMID: 27451856

42. Spencer SE, Valentin-Bon IE, Whaley K, Jerse AE. Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J Infect Dis. 2004; 189(3):410–9. https://doi.org/10.1086/381125 PMID: 14745698

43. Gulati S, Zheng B, Reed GW, Su X, Cox AD, St Michael F, et al. Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection. PLoS Pathog. 2013; 9(8):e1003559. https://doi.org/10.1371/journal.ppat.1003559 PMID: 24009500

44. Liu Y, Hammer LA, Liu W, Hobbs MM, Zielke RA, Sikora AE, et al. Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model. Mucosal Immunol. 2017; 10(6):1594–608. https://doi.org/10.1038/mi.2017.11 PMID: 28272393

45. Shaugnessy J, Gulati S, Agarwal S, Unemo M, Ohnishi M, Su XH, et al. A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol. 2016; 196(4):1732–40. https://doi.org/10.4049/jimmunol.1500292 PMID: 26773149

46. Streeter PR, Corbeil LB. Gonococcal infection in endotoxin-resistant and endotoxin-susceptible mice. Infect Immun. 1981; 32(1):105–10. https://doi.org/10.1128/iai.32.1.105-110.1981 PMID: 6783547

47. Taylor-Robinson D, Furr PM, Hetherington CM. Neisseria gonorrhoeae colonises the genital tract of oestradiol-treated germ-free female mice. Microb Pathog. 1990; 9(5):369–73. https://doi.org/10.1016/0882-4010(90)90071-w PMID: 2129173

48. Finkelstein AE, Walz DT, Batista V, Mizraji M, Risman F, Mishra A. Auranofin. New oral gold compound for treatment of rheumatoid arthritis. Ann Rheum Dis. 1976; 35(3):251–7. https://doi.org/10.1136/ard.35.3.251 PMID: 791161

49. Furst DE. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. Pharmacotherapy. 1983; 3(5):284–98. https://doi.org/10.1002/1875-9114.1983.tb03277.x PMID: 6417628